GSK's Endometrial Cancer Treatment Study Shows Combination Potential

By Anthony O. Goriainoff

GSK said results from a study showed the potential for combinations of its Jemperli cancer treatment in patients with primary advanced or recurrent endometrial cancer.

Endometrial cancer is found in the inner lining of the uterus.

The U.K. pharmaceutical giant said Saturday that positive data from the phase 3 study showed Jemperli(dostarlimab)-based regimens could benefit a larger set of patients with endometrial cancer.

The company said dostarlimab plus chemotherapy was the only immuno-oncology combination to show statistically significant and clinically meaningful overall survival rate in the overall population. It added that it saw a 31% reduction in risk of death and a 16.4-month improvement in the median overall survival rate with dostarlimab plus chemotherapy versus chemotherapy alone, and a 37% reduction in risk of disease progression or death.

"Our goal is to continue to identify ways to use dostarlimab alone and in combination with other therapies to help improve outcomes for patients with limited treatment options," the company said.

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

(END) Dow Jones Newswires

March 18, 2024 03:34 ET (07:34 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.